Background STEP-HFpEF, a 52 week trial conducted in patients with obesity phenotype of
heart failure with preserved ejection fraction (HFpEF) and no type 2 diabetes, examined the …

Background Many therapies for heart failure (HF) have shown differential impact across the
spectrum of left ventricular ejection fraction (LVEF). Objectives In this prespecified analysis …

Abstract Background In the Semaglutide Treatment Effect in People with obesity and HFpEF
(STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms …

Background More women than men have heart failure with preserved ejection fraction
(HFpEF). Objectives The purpose of this study was to assess baseline characteristics and …

BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF)
and obesity experience a high burden of symptoms and functional impairment, and a poor …

Background Obesity is associated with adverse cardiac remodeling and is a key driver for
the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) …

Abstract Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide
resulted in multiple beneficial effects in patients with obesity-related heart failure with …

Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition,
particularly among the aging population in the United States, and is associated with …

Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge with
limited treatment options. This review explores the potential of semaglutide, a glucagon-like …

Introduction: Obesity-related heart failure in patients is often associated with high symptom
burden. However, no treatments have been proven to specifically target obesity-related …